|
March 2005
Volume 55
[Index by Author]
| ||
| |
||
| Dalbavancin, a novel second-generation lipoglycopeptide agent for the treatment of serious Gram-positive infections | ||
This supplement has been sponsored by Vicuron Pharmaceuticals |
||
| |
||
Disclaimer: Every effort has been made to faithfully reproduce the abstracts as submitted. However, no responsibility is assumed by the organizers for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, we recommend that independent verification of diagnoses and drug doses should be made.